The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
The U.S. Air Force's top general says he hasn't received direction to send additional bombers to the Middle East after what is believed to be Iranian attacks on Saudi Arabian...Defenseread more
Facebook has partnered with Ray-Ban maker Luxottica to develop augmented-reality glasses code-named 'Orion', people familiar with the matter told CNBC.Technologyread more
"I believe the path to 'health care for all' is a path following the lead of the Affordable Care Act," House Speaker Nancy Pelosi tells Jim Cramer.Health and Scienceread more
The pet food and product retailer posted net sales of $1.15 billion, topping estimates of $1.13 billion, according to a survey of analysts by Refinitiv.Retailread more
E-cigarette maker Juul Labs Inc.'s sales have been halted on two websites in China, just days after it launched in the world's biggest tobacco market.Biotech and Pharmaceuticalsread more
Check out which companies are making headlines after the bell on Wednesday:
Intra-Cellular Therapies plummeted 69 percent after the market closed Wednesday. The biopharmaceutical company announced top-line results from the second phase 3 clinical trial on a treatment for schizophrenia. The medicine at the center of the trial, ITI-007, "did not separate from the placebo ... in part due to an unusually high placebo response."
"We plan to request a meeting with the U.S. Food and Drug Administration's Division of Psychiatry Products to discuss the regulatory path for this first-in-class investigation agent," the company said in a press release. The stock closed up 2 percent, trading at $42.35 on Wednesday.
Shares of National Beverage inched up about 2 percent after the bell. The LaCroix maker took a hit Wednesday after Glaucus Research revealed a short position in the company. The stock closed down 8.2 percent, trading at $42.67.
Progress Software plunged about 10 percent in after-hours trading Tuesday. The company reported quarterly earnings of 44 cents per share compared to analyst estimates of 45 cents, according to Factset. Revenue was $102.4 million, below Factset's analyst estimates of $104.7 million. The software company also initiated a quarterly dividend of 12.5 cents per share, payable on December 15.
Pier 1 Imports spiked 7.5 percent after it reported earnings Wednesday. The retail chain reported a net loss of 5 cents per share on sales of $405.8 million. Factset showed analysts estimated a net loss of 6 cents per share on revenue of $405.5 million. The company adjusted its full-year guidance to fall within a range of 24 cents per share and 32 cents per share.